Annual report pursuant to Section 13 and 15(d)

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details)

v3.24.1
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Tax and related expenses $ 15,165  
Other 3,897 $ 3,080
Total accrued expenses and other current liabilities 38,473 14,764
Supply Agreement | Vaxcyte, Inc. ('Vaxcyte")    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaboration and license agreements and supply agreement accruals 6,933 4,830
CMO    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaboration and license agreements and supply agreement accruals 8,195 3,900
Clinical Trials    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Collaboration and license agreements and supply agreement accruals $ 4,283 $ 2,954